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Abstract The intracellular expression of single-chain Fv anti-
body fragments (scFv) in eukaryotic cells has an enormous
potential in functional genomics and therapeutics [Marasco
(1997) Gene Ther. 4, 11^15; Richardson and Marasco (1995)
Trends Biotechnol. 13, 306^310]. However, the application of
these so-called intrabodies is currently limited by their unpre-
dictable behavior under the reducing conditions encountered
inside eukaryotic cells, which can affect their stability and
solubility properties [Wo«rn et al. (2000) J. Biol. Chem. 275,
2795^2803; Biocca et al. (1995) Bio/Technology 13, 1110^1115].
We present a novel system that enables selection of stable and
soluble intrabody frameworks in vivo without the requirement or
knowledge of antigens. This system is based on the expression of
single-chain antibodies fused to a selectable marker that can
control gene expression and cell growth. Our results show that
the activity of a selectable marker fused to well characterized
scFvs [Wo«rn et al. (2000) J. Biol. Chem. 275, 2795^2803]
correlates with the solubility and stability of the scFv moieties.
This method provides a unique tool to identify stable and soluble
scFv frameworks, which subsequently serve as acceptor back-
bones to construct intrabody complementarity determining
region libraries by randomization of hypervariable loops.
ß 2001 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Antibodies are highly specialized proteins with the ability to
speci¢cally bind a wide array of molecules. They are normally
secreted into the extracellular environment or remain mem-
brane-bound on the cell surface to serve as antigen receptors.
Recent progress in recombinant antibody technology has
turned the antibodies into important tools for many applica-
tions in biotechnology and medicine. A favorite antibody
form in these ¢elds is the recombinant single-chain Fv anti-
body fragment (scFv), which is expressed from a single cDNA
and is composed of an antibody variable light-chain tethered
to a variable heavy-chain sequence by a £exible linker [5,6].
Each variable domain contains three hypervariable loops
known as complementarity determining regions (CDRs) that
are embedded in the framework sequence and contribute the
antigen-binding pocket. This minimal antibody form generally
binds an antigen with the same speci¢city and a⁄nity as the
full-size parental antibody. In addition to being secreted, the
scFv form can also be expressed in the cytoplasm and targeted
to any compartment of any eukaryotic cell by omitting or
changing the speci¢c signal sequence [1,2]. Intracellularly ex-
pressed scFvs are called intrabodies. The potential of intra-
bodies is becoming increasingly recognized, in particular in
the ¢eld of functional genomics, where they can be used as
powerful tools to speci¢cally target intracellular proteins, thus
enabling the analysis of protein function in vivo. Intrabodies
could modulate molecular events inside the cell by, for exam-
ple, directly blocking a protein activity or by interfering with
protein^protein interactions (see [7^11] for representative ex-
amples).
Despite this exciting perspective and a few examples of
successful applications, the e⁄cient cytoplasmic expression
of scFvs is generally limited by their instability and insolubil-
ity. The reducing environment of the cytoplasm prevents the
formation of the conserved intrachain disul¢de bridges, thus
rendering a high percentage of scFvs unstable and, as a con-
sequence, non-functional inside the cell [4,12]. Stability and
solubility of single-chain antibodies in a reducing environment
represent therefore a major problem for the application of
intrabodies as potential modulators of protein function in
vivo. One approach to solve this problem can be provided
by constructing randomized CDR libraries on scFv frame-
works that have been selected for high stability and solubility
in an intracellular environment.
The system presented here, named ‘Quality Control’, allows
the selection of stable and soluble intrabodies in yeast inde-
pendently of their antigen-binding speci¢city. We show that
the activity of a selectable marker protein fused to an scFv
strictly correlates with the stability of the scFv moiety. Since
the selectable marker used in our assay can control cell
growth by activating transcription of a conditionally essential
gene, yeast colony formation on a plate, or growth in liquid
culture, depends on the presence of a stable and soluble scFv
antibody fragment inside the cell. Here, we validate our ‘Qual-
ity Control’ system by testing various anti-GCN4 scFvs that
have previously been characterized for stability, solubility and
their in vivo performance [3]. We show that only stable and
soluble scFv moieties permit activation of the speci¢c reporter
genes. This approach allows e⁄cient screens of scFv libraries
to isolate ‘super-stable’ frameworks suitable for intracellular
applications.
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2. Materials and methods
2.1. Plasmids and yeast strains
The plasmids expressing the various anti-GCN4 scFv fusion pro-
teins were constructed as follows. The Gal4 activation domain (AD)
(amino acids 768^881) was ampli¢ed by polymerase chain reaction
(PCR) using pGAD424 (Clontech) as template. Both primers (up-
stream primer: 5P-CCA TGG GCC CAA GCT TTG CAA AGA
TGG ATA AAG-3P ; downstream primer: 5P-TTT GGG CCC GAA
GAA CCG CCA CCA CCA GAA CCG CCT CCA CCA GAG CCA
CCA CCA CCA GGC CTG ATC TCT TTT TTT GGG TTT GGT
G-3P) contain an ApaI site suitable for cloning the Gal4 AD including
the SV40 T-antigen nuclear localization signal N-terminal to the dif-
ferent scFv variants in the context of pESBA-Act [3]. The AD and the
single-chain antibodies are seperated by a (GGGS)3 linker encoded by
the downstream primer. The DNA fragments encoding amino acids
263^352 of Gal11 or Gal11P were ampli¢ed by PCR with the primer
pair 5P-CAT GCC ATG GTT CCT CAA CAG CAG CAA ATG
CAA C-3P and 5P-CAT GCC ATG GCG CTA GCC AAA GCT
TGG ATT TTT CTC AGG-3P. The constructs pSO23 and pSO32
[13] were used as templates for the Gal11 wild-type fragment or the
Gal11P sequence, respectively. Both primers are £anked by an NcoI
site in order to clone the digested PCR product upstream of the Gal4
AD. All clones were sequenced to con¢rm in-frame fusion and correct
orientation of the inserts. The mammalian expression vectors encod-
ing the various Gal4 (1^147)-VP16-scFv fusion proteins are based on
a plasmid expressing Gal4 (1^147) under the control of the CMV
promoter. The VP16 AD was ampli¢ed by PCR with the primers
5P-ATC GGA TCC CAG CCC CCC CGA CCG ATG TCA GCC
TG-3P and 5P-TTC CGT CGA CCG GAT ATC GAA CCA CCA
CCA CCG TAC TCG TCA ATT CCA AG-3P and cloned via BamHI
and SalI downstream of Gal4 (1^147). All scFv variants cloned in
pESBA-Act [3] were ¢rst digested with NcoI and subsequently treated
with Klenow in order to obtain blunt ends. The same DNA was then
digested with SalI and the released scFv inserts (NcoI [blunt ended]^
SalI) were cloned downstream of VP16 of the EcoRV^SalI-digested
Gal4 (1^147)-VP16 vector. The yeast expression vectors encoding the
LexA-AD-scFv fusions were obtained by cloning a LexA fragment
and the respective scFv fragment fused to the AD of Gal4 into
pAB125 digested with HindIII and SalI. The LexA moiety was re-
leased by HindIII^SmaI digestion of plex113 and the AD-scFv frag-
ment (NcoI [blunt ended]^SalI) was obtained from a plasmid express-
ing the AD-scFv fusion (see above). The yeast-integrating reporter
plasmid pDE103, which carries the divergently oriented LacZ and
HIS3 genes under the control of the natural UASG from the
GAL1^GAL10 regulatory sequences, was linearized at the A£II site
in the HIS3 3P untranslated region (UTR) and integrated into the
his3v200 locus of JPY9 [14] resulting in YDE172 (MATK ura3-52
leu2 v 1 trp1d63 lys2 v 385 gal4v 11). The integrating reporter plas-
mid pDE200 [14] drives the expression of LacZ and HIS3 from a
bidirectional promoter with six LexA-binding sites. This plasmid
was linearized at the A£II site in the HIS3 3P UTR and integrated
into the his3v200 locus of JPY9 resulting in YDE173.
2.2. L-Galactosidase assays
Gene expression in yeast was monitored by using liquid L-galacto-
sidase assays as previously described [3]. All assays were conducted
with duplicate or triplicate samples and were repeated at least once.
Normalized L-galactosidase activity obtained with the V-graft fusion
proteins was generally set to 100% in all experiments.
2.3. Western blot analysis of scFv fusion proteins
5 ml cultures were grown to an optical density (OD600) of 2. One
half of the culture was used for the preparation of whole cell extracts
as described [15]. The other half was subjected to a gentle isolation of
soluble proteins with Y-PER1 (a Yeast Protein Extraction Reagent
from Pierce) as described previously [3]. Samples of soluble and whole
cell extracts were subjected to sodium dodecyl sulfate^polyacrylamide
gel electrophoresis and blotted on nitrocellulose membranes, following
standard protocols. An antibody from Santa Cruz Biotechnology, Inc.
speci¢c for the AD of Gal4 (Gal4AD (sc-1663)) was used to detect the
Gal11P-Gal4AD-scFv fusion proteins.
2.4. Mammalian cell cultures, transfection and luciferase assays
HeGlu cells [16] were cultured in Dulbecco’s modi¢ed Eagle’s me-
dium supplemented with 2.5% fetal calf serum (Gibco), 100 U/ml
penicillin and 100 U/ml streptomycin and 2 mM L-glutamine. Tran-
sient transfections were carried out by the calcium phosphate method
[17] in 100-mm tissue culture plates with 5 Wg of a CMV promoter
driven Gal4 (1^147)-VP16 scFv expression plasmid and 1 Wg of a
LacZ expression vector as reference for transfection e⁄ciency. The
following day, cells were washed and 48 h after transfection they
were harvested. Cells were resuspended in 100 Wl extraction bu¡er
(100 mM potassium phosphate pH 7.8, 1 mM dithiothreitol) and
lysed by freezing and thawing three times. Supernatants were clari¢ed
by centrifugation (5 min, 13 000 rpm), 10 Wl of extract was mixed with
100 Wl luciferase assay solution (Promega) and analyzed in a lumi-
nometer (EGpG Berthold Lumat LB 9507). L-Galactosidase assay was
performed according to standard methods using 50 Wl of the extract
and luciferase units were normalized according to L-galactosidase val-
ues. All measurements were performed from two independent trans-
fections. Luciferase activity obtained with the V-graft fusion protein
was arbitrarily set to 100%.
3. Results and discussion
The technique presented here to identify intracellularly sta-
ble and soluble scFv frameworks is based on the assumption
Fig. 1. Schematic representation of the ‘Quality Control’ system to
select stable and soluble scFv antibody fragments independently of
their antigen-binding speci¢city. An scFv is fused to a selectable
marker protein comprising a transcriptional AD and a peptide de-
rived from Gal11P, which can mediate the speci¢c interaction with
the DNA-bound Gal4 (1^100) fragment. The conceptual basis of
the system is that the activity of the fusion protein is dependent on
the stability and solubility of the scFv moiety. A: A fusion protein
carrying a stable and soluble scFv is tethered to DNA via the Gal4
(1^100)^Gal11P interaction where it activates transcription of the di-
vergently oriented HIS3 and lacZ reporter genes (bent arrows). B:
Unstable and/or insoluble scFv moieties cause inactivation of the
whole fusion protein (dashed line), thus resulting in the lack of ex-
pression of the reporter genes (crossed arrows).
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that the stability and the solubility (and therefore the activity)
of a fusion protein composed of a constant, selectable marker
fused to an scFv are determined by the quality of the scFv
moiety. To test this hypothesis, we fused a number of well
characterized scFvs to a marker protein that is composed of a
peptide linked to the transcriptional activation domain (AD)
of Gal4 (Fig. 1). The peptide was derived from the mutant
form of the yeast protein Gal11 called Gal11P. It has previ-
ously been shown that only the mutant Gal11P peptide, but
not the wild-type sequence, speci¢cally interacts with the di-
merization region of the DNA-binding Gal4 (1^100) fragment
[18]. The AD of Gal4 is known to activate transcription when
tethered to DNA [19]. According to the hypothesis outlined
above, a fusion protein bearing a soluble and stable scFv
Fig. 2. Reporter gene activation is dependent on the stability and solubility of various anti-GCN4 scFv variants. A: L-Galactosidase assay to
measure activation of the lacZ reporter gene. The reporter yeast strain was transformed with plasmids expressing one of the indicated scFv hy-
brid proteins together with the Gal4 (1^100) fragment. Gal4 full-length and an empty vector were used as a positive and a negative control, re-
spectively. A hybrid protein carrying a peptide derived from the wild-type Gal11 (11wt-AD-V-graft), which is unable to interact with Gal4 (1^
100), was also used as a control. The soluble and highly stable 6-, V-, and U-graft scFv variants enabled the respective 11P-AD fusion proteins
to strongly activate the lacZ reporter gene, while the less stable scFv variants (anti-GCN4wt, anti-GCN4H-R66K, anti-GCN4SS- -) did not
allow signi¢cant reporter gene activation. Relative L-galactosidase activity (rel. L-gal activity) elicited by the 11P-AD-V-graft fusion protein was
arbitrarily set to 100%. B: Western blot analysis showing the correlation between solubility of the scFv fusion proteins and activation of the
lacZ reporter gene. The fusion proteins (11P-AD-scFv) were detected with an antibody speci¢c for the AD of Gal4. The open arrow indicates
a background band present in all lanes including the ‘empty vector’ control not expressing any fusion protein. Only the graft variants (11P-
AD-6-graft, 11P-AD-U-graft, 11P-AD-V-graft) were detected in the soluble fraction (indicated with a black arrow) while all scFv fusion pro-
teins were very abundant in whole cell extracts. C: Growth on selective plates containing 3-AT correlates with the gene activation potential of
the tested scFv fusion proteins. Yeast cells transformed with the same set of plasmids as in A were spread on selective plates lacking histidine
and supplemented with 0 mM or 20 mM 3-AT solutions. Cell growth was monitored after 48 and 96 h incubation at 30‡C.
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should be tethered to DNA via the Gal4 (1^100)^Gal11P
interaction and, thus, activate transcription of the reporter
genes.
Several de¢ned scFv fragments displaying very similar anti-
gen-binding properties, but di¡erent in vitro stability and in
vivo performance [3], were fused to the Gal11P-Gal4AD
marker protein. These scFv variants bind speci¢cally the so-
called leucine zipper of the yeast transcription factor Gcn4.
The original anti-GCN4 wild-type (anti-GCN4wt) scFv was
obtained by ribosome display from a library constructed from
an immunized mouse [20]. Several di¡erent framework var-
iants of this anti-GCN4 scFv have been constructed and de-
scribed in our recent work [3]. These variants have been ex-
tensively characterized for their in vitro stability and
solubility, as well as for their in vivo performance as inhib-
itors of the Gcn4 transcriptional activity in yeast [3]. These
scFv fusion proteins and the DNA-binding Gal4 (1^100) frag-
ment were co-expressed in a yeast strain (YDE172) containing
the reporter genes HIS3 and lacZ under the control of four
Gal4-binding sites (Fig. 1). Yeast cells expressing these di¡er-
ent proteins were grown in culture and subjected to a L-ga-
lactosidase assay to quantify expression of the lacZ reporter
gene. Cells expressing full-length Gal4 or carrying an empty
vector were used as positive and negative controls, respec-
tively. A fusion protein carrying a Gal11 wild-type peptide,
which does not interact with Gal4 (1^100), was used as an
additional control. Fig. 2A shows that the Gal11P fusion
proteins bearing the stable scFv moieties called V-graft and
U-graft [3] were able to strongly activate lacZ expression,
while those harboring the unstable scFvs (anti-GCN4wt,
anti-GCN4H-R66K, anti-GCN4SS-- [3]) were unable to stim-
ulate lacZ expression. The so-called 6-graft, which di¡ers
from the V-graft by only three amino acids in the framework
sequence, displayed an approximately 40% better in vivo per-
formance than the V-graft (Fig. 2A), which is similar to the
performance observed in antigen-dependent in vivo interac-
tion experiments (our unpublished results).
The solubility of the di¡erent Gal11P-Gal4AD-scFv fusion
proteins in yeast was assessed by Western blot analysis. Two
di¡erent protocols were applied for the preparation of yeast
cell extracts (see Section 2). One protocol facilitates isolation
of soluble proteins, while the other protocol is commonly used
to prepare whole cell extracts. Signi¢cant amounts of proteins
were detected in the soluble fraction in the case of the 6-, U-,
and V-graft variants fused to Gal11P-Gal4AD (Fig. 2B). The
other fusion proteins comprising the unstable scFvs (anti-
GCN4wt and anti-GCN4H-R66K [3]) appeared to be com-
pletely insoluble since they were not detectable in the fraction
containing soluble proteins. Nevertheless, all Gal11P-Gal4-
AD-scFv fusion proteins were very abundant and easily de-
tectable in whole cell extracts. The observed di¡erences in
solubility between the scFv fusion proteins were highly repro-
ducible and correlated with results of previous experiments in
which solubility was assessed for the non-fusion scFvs [3].
These results, taken together with the biochemical charac-
terization of the various scFvs [3], show a correlation between
reporter gene activation (L-galactosidase activity) by the fu-
sion protein and the in vitro stability and solubility of the
single-chain moiety. The Gcn4 antigen-binding activities of
the scFv antibody fragments in the context of these fusion
proteins were tested by comparing their ability to inhibit
Gcn4 function in yeast with that of the originally character-
ized scFvs [3]. All scFv hybrid proteins tested here reduced
Gcn4-dependent gene expression to the same extend as the
original, non-fusion scFvs (data not shown). Thus, the fusion
of a marker protein did not alter the biological activity of the
scFv antibody fragments.
The reporter strain used in this study (YDE172) also con-
tains the HIS3 gene under the control of four Gal4-binding
sites (Fig. 1). Activation of this reporter gene allows growth
selection on plates lacking histidine and containing 3-amino-
triazole (3-AT), which is a competitive inhibitor of the HIS3
gene product. The same yeast cells that were subjected to the
liquid L-galactosidase assay (Fig. 2A) were spread on selective
Fig. 3. Stability and solubility of various anti-GCN4 scFv frame-
work variants determine the activity of di¡erent types of selectable
marker proteins. A yeast strain carrying the lacZ reporter gene out-
lined at the top of the panel was transformed with plasmids express-
ing the indicated anti-GCN4 scFv variants fused to a transcriptional
activator comprising the DNA-binding LexA and the AD of Gal4.
The strong activator LexA-Gal11 [18] and an empty vector were
used as positive and negative controls, respectively. Relative L-galac-
tosidase activity (rel. L-gal activity) elicited by the LexA-AD-V-graft
fusion protein was arbitrarily set to 100%.
Fig. 4. Stability and solubility of various anti-GCN4 scFv frame-
work variants determine the activity of a transcriptional activator in
mammalian cells. HeLa cells carrying the integrated luciferase re-
porter gene depicted at the top of the panel were transfected with
plasmids expressing the indicated anti-GCN4 scFv variants fused to
the transcriptional activator Gal4 (1^147)-VP16. Gal4 (1^147)-VP16
and Gal4 (1^147) alone were used as positive and negative controls,
respectively. Relative luciferase activity (rel. luciferase activity) elic-
ited by the Gal4 (1^147)-VP16-V-graft fusion protein was arbitrarily
set to 100%.
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plates lacking histidine and containing di¡erent concentra-
tions of 3-AT, as well as on non-selective control plates.
Under non-selective conditions, no di¡erence in the growth
rate could be observed between yeast cells harboring the var-
ious scFv fusion variants. Under selective conditions, a 20
mM 3-AT concentration was already su⁄cient to suppress
growth of yeast cells carrying an empty vector or expressing
a fusion protein with unstable and insoluble scFv moieties
(Fig. 2C). Even after the observation period of 4 days, yeast
cells expressing unstable fusion variants were unable to grow
in the presence of 3-AT concentrations ranging from 10 mM
to 60 mM (Fig. 2C and data not shown). In contrast, stable
and soluble scFv moieties such as the V-graft, the U-graft, and
the 6-graft endowed the respective fusion proteins with the
ability to stimulate growth of the yeast cells under these se-
lective conditions (Fig. 2C). These results indicate that this
growth selection procedure allows to distinguish intracellu-
larly stable scFvs from unstable ones.
We then tested whether the correlation between the in vivo
activity of the Gal11P-Gal4AD selectable marker and the
stability of the scFv antibody fragment that was fused to it
would also be observed with another fusion protein bearing a
di¡erent selectable marker. For this purpose, we substituted
the Gal11P peptide of the Gal11P-Gal4AD-scFv fusion pro-
teins described above with the DNA-binding LexA protein.
These fusion proteins, if stable and active, should directly and
speci¢cally bind DNA and activate transcription from a near-
by promoter. The LexA fusion proteins were expressed in a
yeast strain YDE173 containing a lacZ reporter gene under
the control of six LexA-binding sites. Activation of the re-
porter gene was quanti¢ed by L-galactosidase assays. Fig. 3
shows that, also in this context, the stability and the solubility
of the scFv antibody fragments determined the functionality
of the hybrid proteins in yeast cells (compare Fig. 3 with Fig.
2A). In addition, similar results as in Fig. 2C were obtained
from a growth selection assay with the LexA fusion proteins
expressed in YDE173 (data not shown).
To determine whether these characterized scFvs have the
same properties when expressed in mammalian cells, we
adapted our ‘Quality Control’ system to mammalian expres-
sion vectors. We modi¢ed our system such that the scFv frag-
ments tested in yeast (see above) were fused to a strong mam-
malian transcriptional activator consisting of the Gal4 DNA-
binding domain and the VP16 AD (Gal4 (1^147)-VP16) [21].
HeGlu cells, which are HeLa cells carrying an integrated lu-
ciferase reporter gene under the control of Gal4-binding sites
[16], were transfected with these constructs as well as with a
plasmid expressing Gal4 (1^147)-VP16 alone (positive control)
or with an empty vector (negative control). After 48 h of
incubation, reporter gene expression was monitored by mea-
suring luciferase activity (Fig. 4). The relative levels of activa-
tion of the luciferase reporter gene by the di¡erent scFv fusion
proteins correlated with the levels of L-galactosidase activities
elicited by the respective scFv fusion proteins in yeast. The V-
graft and U-graft, which were stable and soluble in yeast and
thus allowed gene activation by the respective fusion proteins,
also mediated strong activation of the reporter gene in mam-
malian cells. The other scFv framework variants, which did
not allow reporter gene activation in yeast, could also not
signi¢cantly stimulate reporter gene expression in mammalian
cells (compare Fig. 4 with Fig. 3). Thus, our ‘Quality Control’
system allows us to exploit the technical advantages of the
yeast cells to identify intrabodies that are also functional in
mammalian cells.
4. Conclusion
Low solubility and instability represent a major stumbling
block for the e⁄cient exploitation of scFv antibody fragments
to knock out or modulate protein function inside eukaryotic
cells. So far, no reliable rules are available to make predic-
tions about antibody structures that can tolerate the reducing
environment of the cytoplasm, and individual biochemical
analysis of scFvs is a long and tedious procedure. Our goal
was to develop a system that allows a high-throughput screen
of scFv antibody fragments to identify those that are highly
stable in an intracellular (reducing) environment. In order to
screen a large number of diverse scFv sequences, the selection
assay could not rely on antibody^antigen interactions. This is,
to our knowledge, the ¢rst report on an in vivo method to
identify and analyze intrabodies for stability and solubility
independently of their antigen-binding properties. To this
end, we have constructed fusion proteins composed of scFv
sequences fused to a constant marker that provides a select-
able activity in yeast by controlling expression of de¢ned re-
porter genes. Our results indicate that the overall stability and
the function of the fusion protein are determined by the scFv
portion. We show that the degree of reporter gene activation
is directly proportional to the stability and solubility of the
single-chain antibody and can be quanti¢ed by measuring ex-
pression of the reporter genes. Analysis of the soluble fraction
for each fusion protein revealed a strong correlation between
solubility and reporter gene activation. Thus, our ‘Quality
Control’ system is suitable to validate single-chain antibodies
that can cope with intracellular conditions. With the possibil-
ity to perform growth selection assays, our system allows to
rapidly and e⁄ciently screen single-chain antibody libraries to
isolate a set of ‘super-stable’ frameworks. Such frameworks
subsequently serve as acceptor backbones to construct CDR
libraries by randomization of one or more hypervariable
loops. Additionally, our system can be used in an ‘intrabody
evolution process’ to improve the in vivo performance of spe-
ci¢c single-chain antibodies that are poorly stable, and thus
only weakly functional under reducing conditions.
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